Press Releases
Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing, solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion,...
Press Releases
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
Novartis, a leader in immuno-dermatology and rheumatology, announced the EC has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The recommended dose for children up...
Press Releases
Raremark launches the Xperiome patient-powered knowledge platform to deliver new therapies faster and smarter
Raremark®, the leading online patient community in rare disease, has launched its patient-powered knowledge platform Xperiome™ to help the pharmaceutical industry deliver innovative new therapies faster and smarter.
The Xperiome platform expands on Raremark’s vision of a world in which...
Packaging & Labelling
Sharp has achieved landfill-free status across its global facility network
Sharp, part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has achieved landfill-free status across its global facility network.
As part of a broader, long-term commitment to the environment and sustainability, a series of...
Drug Research
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in phase 1 clinical development for non-small cell...
Clinical Trials
AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention
AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to...
Press Releases
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Sanofi and GSK have reached an agreement, subject to final contract, with the UK government for the supply of up to 60 million doses of a COVID-19 vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read